Higher-Dose (23 mg/day) Donepezil Formulation for the Treatment of Patients with Moderate-to-Severe Alzheimer's Disease

References

• . Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimer's Association website, http://www.alz.org/alzheimers_disease_facts_and_figures.asp.pdf. Accessed June 21, 2012
   Google Scholar
• . Bergvall N, Brinck P, Eek D, . Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease. Int Psychogener. 2011;23(1):73–85
   PubMed Web of Science ®Google Scholar
• . Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010;18(10):917–927
   PubMed Web of Science ®Google Scholar
• . Gaugler JE, Yu F, Krichbaum K, Wyman JF. Predictors of nursing home admission for persons with dementia. Med Care. 2009;47(2):191–198
   PubMed Web of Science ®Google Scholar
• . Feldman H, Gauthier S, Hecker J, ; Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc. 2003;51(6):737–744
   Google Scholar
• . Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537–545
   PubMed Web of Science ®Google Scholar
• . Herrmann N, Cappell J, Eryavec GM, Lanctot KL. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs. 2011;25(5):425–433
   Google Scholar
• . Geldmacher DS, Provenzano G, McRae T, Mastey YIeni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51(7):937–944
   PubMed Web of Science ®Google Scholar
• . Aricept [package insert]. Teaneck, NJ: Eisai Inc.; 2006
   Google Scholar
• . Namenda [package insert]. St. Louis, MO: Forest Laboratories, Inc.; 2007
   Google Scholar
• . Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351(1):56–67
   PubMed Web of Science ®Google Scholar
• . Tariot PN, Farlow MR, Grossberg GT, ; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–324
   PubMed Web of Science ®Google Scholar
• . Xiong G, Doraiswamy PM. Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics. 2005;60(6):22–26
   Google Scholar
• . Whitehouse PJ. The cholinergic deficit in Alzheimer's disease. J Clin Psychiatry. 1998;59( suppl 13):19–22
   PubMed Web of Science ®Google Scholar
• . Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MRKoeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000;48(3):391–395
   PubMed Web of Science ®Google Scholar
• . Kaasinen V, Nagren K, Järvenpää T, . Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol. 2002;22(6):615–620
   PubMed Web of Science ®Google Scholar
• . Davis KL, Mohs RC, Marin D, . Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281(15):1401–1406
   PubMed Web of Science ®Google Scholar
• . Homma A, Imai Y, Tago H, . Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008;25(5):399–407
   PubMed Web of Science ®Google Scholar
• . Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004;19(7):624–633
   Google Scholar
• . Nozawa M, Ichimiya Y, Nozawa E, . Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics. 2009;9(2):50–55
   PubMed Web of Science ®Google Scholar
• . Doody RS, Corey—Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008;25(2):163–174
   PubMed Web of Science ®Google Scholar
• . Farlow MR, Salloway S, Tariot PN, . Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–1251
   PubMed Web of Science ®Google Scholar
• . Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57(4):613–620
   PubMed Web of Science ®Google Scholar
• . Winblad B, Kilander L, Eriksson S, ; Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057–1065
   PubMed Web of Science ®Google Scholar
• . Doody RS, Geldmacher D, Farlow M, Sun Y, Moline M, Mackell J. Evaluating the impact of concomitant memantine use on the efficacy and safety of high-dose donepezil (23 mg/d) in patients with moderate and severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012;33(2–3):164–173
   PubMed Web of Science ®Google Scholar
• . Salloway S, Mintzer J, Cummings JL, . Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2012;27(6):421–432
   PubMed Web of Science ®Google Scholar
• . Ferris SH, Schmitt FA, Saxton J, . Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther. 2011;3(3):22
   PubMed Web of Science ®Google Scholar
• . Farlow M, Veloso F, Moline M, . Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol. 2011;11:57
   PubMed Web of Science ®Google Scholar
• . Tariot P, Salloway S, Yardley J, Mackell J, Moline M. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Res Notes. 2012;5(1):283
   Google Scholar
• . Gomolin IH, Smith C, Jeitner TM. Donepezil dosing strategies: pharmacokinetic considerations. J Am Med Dir Assoc. 2011;12(8):606–608
   Google Scholar
• . Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg/d. BMJ. 2012;344:e1086
   Google Scholar